The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Lower – and shorter – efficacy add to serious doubts about the TIL therapy's future.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
There are some remissions, but peripheral neuropathy casts a long shadow.